Arch. Dis. Child

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Archives of Disease in Childhood - Education and Practice 2008;93:71
Copyright © 2008 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Adelsberg, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adelsberg, B.

EVIDENCE-BASED MEDICINE

Review: LABAs are better than leukotriene receptor antagonists when added to inhaled corticosteroids in recurrent asthma

In patients with recurrent asthma, what is the effectiveness of adding long acting β2 agonists (LABAs) or leukotriene receptor antagonists (LTRAs) to inhaled corticosteroids (ICSs)?

Keywords: adrenal cortex hormones; adrenergic β agonists; asthma; leukotriene antagonists

The first 150 words of the full text of this article appear below.

Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006;(4):CD003137.

Clinical impact ratings GP/FP/Primary care âââââââ IM/Ambulatory care âââââââ Allergy & immunology âââââââ Paediatrics âââââââ


METHODS
Formula Data sources: Medline, CINAHL, EMBASE/Excerpta Medica, Cochrane Central Register of Controlled Trials, Cochrane Airways Group Specialised Register (to March 2006), hand searches of respiratory journals and meeting abstracts, and bibliographies of relevant published and unpublished studies and reviews.

Formula Study selection and assessment: randomised controlled trials (RCTs) that evaluated the effectiveness of adding LABAs (salmeterol or formoterol) or LTRAs (montelukast, pranlukast, zafirlukast, or zileuton) to ICSs for recurrent asthma. Rescue and asthma medications were permitted at a constant dose. 15 RCTs (age range 6–79 y) met the selection criteria; 1 RCT included children. Quality assessment was based on the 5 point Jadad scale; 8 RCTs had scores of 5.

Formula Outcomes: number of . . . [Full text of this article]

Bernard Adelsberg

Hamden Internal Medicine Associates, New Haven, Connecticut, USA






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health